This clinical trial is focused on studying infections that occur in the material used to stabilize and heal long bone fractures, known as osteosynthesis material. These infections can happen after surgery when the material is implanted to help the bone heal. The study aims to determine if a shorter course of treatment is as effective as a longer one in managing these infections. The trial involves patients who have undergone surgical procedures to either keep or remove the implant, combined with targeted antimicrobial therapy, which is a treatment using specific antibiotics to fight the infection.
The antibiotics being studied in this trial include moxifloxacin, amoxicillin sodium, daptomycin, cloxacillin, ampicillin, vancomycin, sulfamethoxazole, trimethoprim, meropenem, rifampicin, ceftriaxone, ciprofloxacin, linezolid, clindamycin, teicoplanin, ceftazidime, cefepime, and levofloxacin. Some of these medications are given orally, while others are administered intravenously, which means they are injected directly into a vein. The study will compare the effectiveness and safety of these antibiotics in treating the infections associated with the osteosynthesis material.
Participants in the study will receive either the standard treatment duration or a shorter one, and their progress will be monitored to see how well the infection is controlled. The study will also look at the development of any new infections, the need for additional surgeries, and the overall recovery of the patient’s limb function and quality of life. The trial is expected to continue until the end of 2027, with the goal of providing valuable information on the best treatment strategies for these types of infections.
Spain 
